de.mpg.escidoc.pubman.appbase.FacesBean
English
 
Help Guide Disclaimer Contact us Login
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

MPS-Authors

Sos,  Martin L.
Max Planck Institute of Molecular Physiology, Max Planck Society;

Koker,  Mirjam
Max Planck Institute of Molecular Physiology, Max Planck Society;

Heynck,  Stefanie
Max Planck Institute of Molecular Physiology, Max Planck Society;

Weiss,  Jonathan
Max Planck Institute of Molecular Physiology, Max Planck Society;

Fischer,  Florian
Max Planck Institute of Molecular Physiology, Max Planck Society;

Michel,  Kathrin
Max Planck Institute of Molecular Physiology, Max Planck Society;

Peifer,  Martin
Max Planck Institute of Molecular Physiology, Max Planck Society;

Thomas,  Roman K.
Max Planck Institute of Molecular Physiology, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., et al. (2009). PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research, 69(8): 1, pp. 3256-3261. Retrieved from http://dx.doi.org/10.1158/0008-5472.CAN-08-4055.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0014-03A4-3
Abstract
There is no abstract available